Improving clinical outcomes of chronic hepatitis B virus infection

References

• Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92
   PubMed Web of Science ®Google Scholar
• Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011;54:381-92
   PubMed Web of Science ®Google Scholar
• Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-19
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
   PubMed Web of Science ®Google Scholar
• Chen HL, Chang CJ, Kong MS, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 2004;39:58-63
   PubMed Web of Science ®Google Scholar
• Chu CM, Karayiannis P, Fowler MJ, et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985;5:431-4
   PubMed Web of Science ®Google Scholar
• Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007;46:395-401
   PubMed Web of Science ®Google Scholar
• Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009;29(Suppl 1):100-7
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection 2005;33:136-9
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, et al. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207-9
   PubMed Web of Science ®Google Scholar
• Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-62
   PubMed Web of Science ®Google Scholar
• Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011;141:517-25; 25 e1-2
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Chen CL, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 2012;205:54-63
   PubMed Web of Science ®Google Scholar
• Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084-9
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-74
   PubMed Web of Science ®Google Scholar
• Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-95
   PubMed Web of Science ®Google Scholar
• Chen YC, Chu CM, Yeh CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007;1:267-73
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006;26:142-52
   PubMed Web of Science ®Google Scholar
• Su TH, Chen PJ, Chen TC, et al. The clinical significance of occult hepatitis B transfusion in Taiwan – a look-back study. Transfus Med 2011;21:33-41
   PubMed Web of Science ®Google Scholar
• Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009;50:805-16
   PubMed Web of Science ®Google Scholar
• Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988;260:2231-5
   PubMed Web of Science ®Google Scholar
• Hsu HY, Chang MH, Chen DS, et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301-7
   PubMed Web of Science ®Google Scholar
• Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8
   PubMed Web of Science ®Google Scholar
• Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800
   PubMed Web of Science ®Google Scholar
• Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007;132:1287-93
   PubMed Web of Science ®Google Scholar
• Kao JH, Hsu HM, Shau WY, et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-52
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen TH, Hsu HM, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005;11:7953-7
   PubMed Web of Science ®Google Scholar
• Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-55
   PubMed Web of Science ®Google Scholar
• Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005;2:50-7
   PubMedGoogle Scholar
• Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013;310:974-6
   PubMed Web of Science ®Google Scholar
• Cassidy A, Mossman S, Olivieri A, et al. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines 2011;10:1709-15
   PubMed Web of Science ®Google Scholar
• Su TH, Chen PJ. Emerging hepatitis B virus infection in vaccinated populations: a rising concern? Emerg Microbes Infect 2012;1:e27
   Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
   PubMed Web of Science ®Google Scholar
• Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-79; e1-4
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491-8
   PubMed Web of Science ®Google Scholar
• Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5
   PubMed Web of Science ®Google Scholar
• van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-10
   PubMed Web of Science ®Google Scholar
• Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-9
   PubMed Web of Science ®Google Scholar
• Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-50
   PubMed Web of Science ®Google Scholar
• Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-19
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30
   PubMed Web of Science ®Google Scholar
• Wang CC, Tseng KC, Peng CY, et al. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol 2013;28:46-50
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43
   PubMed Web of Science ®Google Scholar
• EASL. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
   PubMed Web of Science ®Google Scholar
• Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;53:2121-9
   PubMed Web of Science ®Google Scholar
• Su TH, Hsu CS, Chen CL, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther 2010;15:1133-9
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-90
   PubMed Web of Science ®Google Scholar
• Su TH, Liu CJ, Tseng TC, et al. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS One 2013;8:e55916
   Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-9; e3; quiz e13-4
   PubMed Web of Science ®Google Scholar
• Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45:1187-92
   PubMed Web of Science ®Google Scholar
• Su TH, Liu CJ, Yang HC, et al. Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. J Gastroenterol 2014;49:356-62
   PubMed Web of Science ®Google Scholar
• Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67
   PubMed Web of Science ®Google Scholar
• Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci 2014;15:10578-604
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75
   PubMed Web of Science ®Google Scholar
• Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791-9
   PubMed Web of Science ®Google Scholar
• Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol 2012;57:508-14
   PubMed Web of Science ®Google Scholar
• Giannelli G, Bergamini C, Marinosci F, et al. Antifibrogenic effect of IFN-alpha2b on hepatic stellate cell activation by human hepatocytes. J Interferon Cytokine Res 2006;26:301-8
   PubMed Web of Science ®Google Scholar
• Tasci I, Mas MR, Vural SA, et al. Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. Liver Int 2006;26:261-8
   PubMed Web of Science ®Google Scholar
• Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7
   PubMed Web of Science ®Google Scholar
• Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52
   PubMed Web of Science ®Google Scholar
• van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006;26:399-405
   PubMed Web of Science ®Google Scholar
• Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007;46:388-94
   PubMed Web of Science ®Google Scholar
• Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-63
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Petraki K, Cholongitas E, et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2005;12:199-206
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-70
   PubMed Web of Science ®Google Scholar
• Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-77
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009;16:265-71
   PubMed Web of Science ®Google Scholar
• Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009;44:470-5
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005;32:173-84
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-91
   PubMed Web of Science ®Google Scholar
• Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-56
   PubMed Web of Science ®Google Scholar
• Eun JR, Lee HJ, Kim TN, et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53:118-25
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537-47
   PubMed Web of Science ®Google Scholar
• Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis b treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-61
   PubMed Web of Science ®Google Scholar
• Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013;62:760-5
   PubMed Web of Science ®Google Scholar
• Gordon SC, Lamerato LE, Rupp LB, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885-93
   PubMed Web of Science ®Google Scholar
• Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis b-a nationwide cohort study. Gastroenterology 2014;147:143-51; e5
   PubMed Web of Science ®Google Scholar
• Su TH, Hu TH, Lin CC, et al. Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long-term entecavir therapy - An interim report of C-TEAM study. Hepatology 2013;58; Abstract 189
   PubMedGoogle Scholar
• Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109-16
   PubMed Web of Science ®Google Scholar
• Kim SS, Hwang JC, Lim SG, et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis b viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gasteroenterol 2014;109(8):1223-33
   PubMed Web of Science ®Google Scholar
• Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774-80
   PubMed Web of Science ®Google Scholar
• Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82
   PubMed Web of Science ®Google Scholar
• Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-50
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32
   PubMed Web of Science ®Google Scholar
• Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009;137:1680-6
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013;62:290-8
   PubMed Web of Science ®Google Scholar
• Chien RN, Peng CY, Kao JH, et al. Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naive Taiwanese patients with chronic hepatitis B. J Gastroenterol Hepatol 2014;29:185-92
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Su TH, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 2012;206:1521-31
   PubMed Web of Science ®Google Scholar
• Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73
   PubMed Web of Science ®Google Scholar
• Chaung KT, Ha NB, Trinh HN, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-70
   PubMed Web of Science ®Google Scholar
• Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96
   PubMed Web of Science ®Google Scholar
• Liu CJ, Wang CC, Yang SS, et al. Entecavir plus peginterferon alfa-2a vs. entecavir alone in the treatment of hepatitis B e antigen-positive chronic hepatitis B: an interim report. J Hepatol 2013;58:S308; A758
   Google Scholar
• Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014. [Epub ahead of print]
   Google Scholar
• Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014;20:6262-78
   PubMed Web of Science ®Google Scholar
• Fernandez-Montero JV, Vispo E, Soriano V. Emerging antiretroviral drugs. Expert Opin Pharmacother 2014;15:211-19
   PubMed Web of Science ®Google Scholar
• Tenofovir alafenamide versus tenofovir disoproxil fumarate for treatment of hepatitis B e antigen-positive hepatitis B. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01940471&Search=Search
   Google Scholar
• Tenofovir alafenamide versus tenofovir disoproxil fumarate for treatment of hepatitis B e antigen-negative hepatitis B. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01940341&Search=Search
   Google Scholar
• Lai CL, Ahn SH, Lee KS, et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 2014;63:996-1004
   PubMed Web of Science ®Google Scholar
• Phase 3 study of besifovir. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01937806&Search=Search
   Google Scholar
• Safety and efficacy of gs-9620 for the treatment of chronic hepatitis b virus in virally-suppressed subjects. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02166047&Search=Search
   Google Scholar
• Study of ARC-520 in patients with chronic hepatitis b virus. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02065336&Search=Search
   Google Scholar
• Lin SR, Yang HC, Kuo YT, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 2014;3:e1
   Google Scholar